Retatrutide is a novel multi-agonist peptide that simultaneously activates GIP, GLP-1 and glucagon receptors.
Recommended for:
Clinical studies demonstrate that Retatrutide significantly reduces body weight (up to 24% in some trials), improves insulin sensitivity, and lowers HbA1c levels.
Used for weight reduction in obese patients, improvement of glycaemic control in type 2 diabetes, and correction of metabolic syndrome.
The drug is administered as subcutaneous injections after reconstitution of the lyophilised powder with solvent. Dosage and treatment schedule must be prescribed individually by a physician.
Contraindications:
Side effects:
